AEHR AEHR TEST SYSTEMS Insider Trading

Director Scott Geoffrey Gates sells 60,000 AEHR shares for $5,660,000 on 2026-04-21, reducing stake by 54.5% to 50,000 shares

Scott Geoffrey Gates, a Director, executed 2 separate sales totaling 60,000 shares for $5,660,000 on 2026-04-21 at blended average price of $94.33, reducing his holdings from 110,000 shares to 50,000 shares—a 54.5% reduction. This sale comes at the stock's 52-week high of $93.72, following exceptional recent momentum (+171.5% over 30 days, +221.0% over 90 days), and occurs just 12 days after Gates executed 3 prior sales at the same ticker on 2026-04-09. The company's fundamentals are weak: revenue of $10,313,000 in the latest quarter with net income of $-3,203,000, annual revenue decline of -11.0%, and company-wide unprofitability in the most recent full fiscal year, against a $2.9B market cap. The concentrated liquidation of a significant portion of holdings at a multiyear high during a period of extreme volatility and deteriorating financial results warrants investor attention to whether the stock's recent surge is sustainable given underlying business challenges.

Director SLAYEN HOWARD T sold 25,000 shares of AEHR at $85.00 for $2.1M amid unprofitability and stock near 52-week high.

SLAYEN HOWARD T, a director, sold 25,000 shares (12.3% reduction) at $85.00 on 2026-04-17, reducing holdings from 203.3K to 178.3K shares. The sale occurred near the stock's 52-week high of $83.86 (current price at +0.0% from peak), following a dramatic 131.0% gain over 30 days and 191.1% over 90 days. Notably, across his entire open-market trade history (cross-ticker), this insider's prior trades show an average 90-day return of -26.8% with a 0.00% win rate, and at AEHR specifically, both prior buys (2023-10-11 and 2024-08-02) resulted in negative 90-day outcomes (-44.4% and -9.2%, respectively). The company's fundamentals present a headwind: AEHR reported quarterly revenue of $10.3M with a net loss of $3.2M, annual revenue declined 11.0% year-over-year, and the company was unprofitable over its most recent full fiscal year. The timing—a substantial reduction at near-peak valuation while the company operates at a loss—warrants investor attention, particularly given the extended rally that preceded the sale.

Director Posedel sold 15,000 shares (15.0K) at $80.72 on 2026-04-16; stock at 52-week high, fundamentals deteriorating

Director Rhea J Posedel sold 15,000 shares (15.0K) for $1,210,800.00 ($1.2M) at $80.72, reducing holdings by 3.5% to 412,000 shares while the stock trades at $80.85—its 52-week high. The sale occurs as AEHR faces material operational headwinds: annual revenue contracted 11.0%, latest quarterly revenue stands at $10,313,000.00 ($10.3M), and the company posted a full-year net loss with latest quarter net income of $-3,203,000.00 ($-3.2M). Posedel's prior timing at this ticker has been constructive—2 of 2 measurable sales executed 90-day windows that saw subsequent stock declines of -24.9% and -29.6%—suggesting the director's historical sales pattern at AEHR has preceded price deterioration. The current sale at peak valuation alongside deteriorating profitability and contracting revenue growth warrants close attention to the directional signal.

CTO Richmond sells 17,011 AEHR shares at $73.18; stock surged +95.4% in 30d, down to $73.22 now; company unprofitable with -11.0% revenue decline

Richmond, AEHR's CTO, sold 17,011 shares at $73.18 on 2026-04-14, reducing his holdings by 8.6%. The sale occurred near the 52-week high of $74.38 and follows an extraordinary 95.4% rally over the prior 30 days and 176.0% surge over 90 days. At AEHR specifically, Richmond's prior two measurable sales (2023-08-09 and 2023-08-10) both proved well-timed at the 90-day mark, with subsequent declines of -50.9% and -53.4% respectively. The sale timing aligns with this pattern of downside-protective exits. However, the underlying business context is deteriorating: the company posted $-3.2M net loss in the latest quarter, -11.0% annual revenue contraction, and remains unprofitable on a full-year basis, with a market cap of $2.3B against $10.3M quarterly revenue. The sharp stock rally into this sale, combined with persistent negative fundamentals, creates a notable divergence between price momentum and operating reality.

Erickson Gayn (CEO) sells 152,824 shares for $10,786,791.67 as stock hits 52-week high; company unprofitable

CEO Erickson Gayn executed 2 separate sales totaling 152,824 shares for $10,786,791.67 at $70.58 on 2026-04-10, reducing his holdings by 43.6% from 350,547 to 197,723 shares. The sales occurred at the 52-week high ($74.38 current price, at +0.0% from 52-week high), following a dramatic 30-day surge of +108.5% and a 90-day gain of +186.4%. This comes as the company reports negative fundamentals: $-3,203,000.00 net income in the latest quarter, annual revenue decline of -11.0%, and full-year unprofitability. While Erickson's prior trades at AEHR showed a 2 of 2 well-timed pattern at the 90-day mark (2023-07-17: 90d -24.5%; 2023-07-14: 90d -11.0%), his cross-ticker track record shows mixed performance (2 prior sells with avg 90d return of -17.7%). The timing coincidence with the 52-week peak and the company's operational deterioration merits scrutiny of near-term price momentum against fundamental weakness.

COO Adil Engineer sold 13,085 shares ($892,182.34) at $68.15–$68.34 on 2026-04-09, reducing holdings 22.5% amid unprofitable operations and 65.9% rally in 30 days.

ENGINEER ADIL, Chief Operating Officer, executed 2 separate sales totaling 13,085 shares for $892,182.34, reducing his stake from 58,254 shares to 45,169 shares post-transaction. The sales occurred at $68.15 and $68.34 on 2026-04-09, near the stock's 52-week high of $70.43, following a pronounced 65.9% gain over the prior 30 days and a 167.6% gain over 90 days. The company is currently unprofitable with a net loss of $3,203,000.00 in the latest quarter and negative full-year net income, alongside an 11.0% decline in annual revenue. The timing of this substantial reduction in executive holdings near a significant price peak—while the company remains in loss-generating operations—merits investor attention to whether fundamental conditions support the current valuation.

Director Scott Geoffrey Gates sells 35,000 shares (25% of holdings) for $2,373,250 at blended avg $67.81 as AEHR stock near 52-week peak

Scott Geoffrey Gates, a director at AEHR Test Systems, executed 3 separate sales totaling 35,000 shares for $2,373,250 on April 9, 2026, reducing his post-transaction holdings to 105,000 shares from 140,000 shares. The sales occurred at a blended average price of $67.81, occurring when the current stock price of $70.43 is at the 52-week high and has surged 65.9% over the prior 30 days and 167.6% over the prior 90 days. Against this backdrop of strong recent price momentum, the director divested a material 25% of his holdings. This sale of a significant block at elevated valuation levels, combined with the company's underlying operational strain—negative net income of $-3,203,000 in the latest quarter, negative full-year net income, and annual revenue decline of -11.0%—represents a divergence between near-term price strength and deteriorating fundamental performance that warrants investor attention.

Director Rhea J. Posedel sold 30,000 shares of AEHR at $70.00 ($2.1M); stock at 52-week high; prior 2 sells at this ticker were 100% well-timed (90d avg -27.3%)

Director Rhea J. Posedel sold 30,000 shares (427.0K shares remaining, -6.6% of holdings) at $70.00 on 2026-04-09, coinciding with AEHR at its 52-week high of $70.43 after a 65.9% surge in 30 days and 167.6% in 90 days. His prior two sales at AEHR on 2023-07-18 and 2023-07-17 were both well-timed at the 90-day mark (-24.7% and -18.4%, respectively), establishing a 100% success rate in timing declines at this ticker. The company remains unprofitable (net income -$3.2M over latest quarter; annual revenue contracted 11.0%), suggesting fundamentals lag the stock's sharp momentum. The convergence of peak pricing, sustained insider selling pattern, and deteriorating financials warrants attention to whether further declines follow the historical precedent.

CTO Donald Richmond II sold 15,751 shares of AEHR at $68.68 for $1.1M; stock at 52-week high, 90d +167.6%

Richmond sold 15,751 shares (15.8K shares) representing 7.3% of his pre-transaction holdings of 214,996 shares (215.0K shares). The sale occurred at $68.68, which matches the 52-week high of $70.43, occurring immediately after a 90-day surge of +167.6% and 30-day gain of +65.9%. Across his cross-ticker track record, Richmond's 2 prior sells showed a 90d well-timed rate of 100.00%, and at AEHR specifically, both prior 2023 sells exhibited negative 90-day returns (−53.4% and −50.9%), indicating a pattern of selling ahead of downturns. However, the company's fundamentals show revenue of $10,313,000.00 ($10.3M) in the latest quarter paired with net income of $-3,203,000.00 ($-3.2M) and annual revenue growth of −11.0%, reflecting ongoing unprofitability and contracting sales. The sale follows a dramatic near-term rally into historical highs, which may explain the execution despite the company's deteriorating operational position.

Director Howard T Slayen buys 20,000 shares of AEHR at $15.50; stock down 73.2% from 52-week high of $53.69.

SLAYEN HOWARD T purchased 20,000 shares at $15.50, increasing his holdings from 200.7K to 220.7K shares (+10.0%). The transaction occurs as AEHR trades 73.2% below its 52-week high and while the stock has rebounded 30.8% over the past 30 days. However, SLAYEN's cross-ticker track record shows poor timing: his prior open-market buy resulted in a 90-day return of -44.4%, with a 0% win rate across all prior buys. At AEHR specifically, his single prior buy on 2023-10-11 also delivered a negative 90-day return of -44.4%. The stock's current price of $14.39 is below the $15.50 transaction price, suggesting this latest purchase has already moved into negative territory.